Gonzalo Rodriguez-Berriguete

6PUBLICATIONS
39CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 12, 2026
SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.

|Apr 30, 2026
Structure-guided optimisation of fenofibrate-derived oxidative phosphorylation inhibitors to modify tumour hypoxia.

|Jul 22, 2025
UPR-induced intracellular C5aR1 promotes adaptation to the hypoxic tumour microenvironment.

Tatsuya Suwa, Kelly Sw Lee, Ian J Chai

|Jan 31, 2025
Repurposing radiosensitising medicines for radiotherapy: an overview.

Jie Man Low, Gonzalo Rodriguez-Berriguete, Geoff S Higgins

|Jan 11, 2024
Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.

Gonzalo Rodriguez-Berriguete, Rathi Puliyadi, Nicole Machado

|Jan 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.

Gonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo

Pageof 1

Frequent Collaborators

4 joint publications

Nicole Machado

3 joint publications

Geoff S Higgins

2 joint publications

Marco Ranzani

2 joint publications

Helen M R Robinson